Background: Pharmacotherapy, including prokinetics and proton pump inhibitors for functional dyspepsia (FD) have limited effectiveness, and their safety has been recently questioned. Chinese herbal medicine (CHM) could be considered as an alternative. A systematic review (SR) of SRs was performed to evaluate the potential effectiveness and safety of CHM. Method: We conducted a comprehensive literature search for SRs with meta-analyses in eight international and Chinese databases. Pooled effect estimation from each meta-analysis was extracted. The AMSTAR instrument was used to assess the methodological quality of the included SRs. Results: A total of 14 SRs of mediocre quality assessing various CHMs, alone or in combination with conventional pharmacotherapy, were included. Meta-analyses showed that CHM was more effective than prokinetic agents for the alleviation of global dyspeptic symptoms. Three specific CHM formulae appeared to show superior results in the alleviation of global dyspeptic symptoms, including Si Ni San, modified Xiao Yao San and Xiang Sha Liu Jun Zi decoction. No significant difference in the occurrence of adverse events in using CHM or pharmacotherapy was reported. Conclusion: CHM can be considered as an alternative for the treatment of FD symptoms when prokinetic agents and proton pump inhibitors are contraindicated. Future trial design should focus on measuring changes in individual dyspeptic symptoms and differentiate the effectiveness of different CHM for postprandial distress syndrome and epigastric pain syndrome. A network meta-analysis approach should be used to explore the most promising CHM formula for FD treatment in the future.
Introduction
Functional dyspepsia (FD) is a common cause of dyspeptic symptoms in the world. 1 The annual incidence of FD approximates 9-10%, while 15% of patients have chronic (>3 months per year) and frequent (>3 episodes per week) symptoms. 1 In the general population, the prevalence of FD is 11.5-14.7%. 2 The prevalence of FD varies between 8% and 23% among Asia population. 3 It can also be as high as 23 .9% in Spain, 32% in the United States (US) and 38-41% in the United Kingdom. 1 FD is more prevalent in women (24.4%) than men (16.6%) and its occurrence was found to increase significantly with age. 5, 6 Currently defined by the Rome IV criteria, FD is categorized into two types: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). 7 PDS is characterized by postprandial fullness and early satiety, while EPS is characterized by epigastric pain or burning. 8 Both do not carry any structural disorders explaining the symptoms. 8 FD does not seem to pose severe or fatal threats to patients. Nevertheless, it greatly reduces patient quality of life; 9 the impact of FD on quality of life is comparable in patients with other chronic diseases such as asthma and inflammatory bowel disease. 10, 11 Moreover, FD incurs heavy economic burdens, attributable to medical care and diagnostic procedure costs. Although the cost data on FD is limited, statistics show that FD created an $18.4 billion medical cost on US patients in 2009. 12 There are several guideline-recommended pharmacotherapies for functional dyspepsia. 8, 9, [13] [14] [15] In a population with high Helicobacter pylori infection rate (>20%), FD patients should be tested and treated by antibiotics if such infection exists. In contrast, in a population with low H. pylori prevalence (<20%), proton pump inhibitor (PPI) should be used for reducing gastric acid secretion in patients with epigastric pain, while prokinetic agents can be used if the symptoms include postprandial fullness or early saiety. 8, 9, [13] [14] [15] However, due to the heterogeneous nature of the symptoms of FD, 16 probably no single pharmacotherapy is able to manage the symptoms fully. 9 Besides, individual symptoms may be caused by different mechanisms. As a result, the same drug may not be able to deal with the same symptom if it is originated from different mechanisms in different patients. 9 In addition, despite being widely in use, prokinetic agents only demonstrate limited effectiveness. For example, acotiamide has a number needed to treat (NNT) of 16 17 for symptom elimination, while the NNT figures of omeprazole and lansoprazole are 9. 18 The side effects of pharmacotherapy also trigger concerns among medical practitioners. Current evidence has shown its association with extra-pyramidal reactions, cardiac arrhythmia and neurological disorders, such as Parkinsonism. [19] [20] [21] [22] There is a need for addressing the effectiveness gap between patients who are experiencing limited benefits from prokinetic agents and PPI, or patients who are contraindicated to them.
Chinese herbal medicine (CHM) is part of the routine in the treatment of FD in China and is gaining popularity in other countries. In traditional Chinese medicine (TCM), FD is equivalently termed as 'distension and fullness' (in Chinese pinyin: Pi Man), 'stomach pain' (in Chinese pinyin: Wei Wan Tong) and 'retention' (in Chinese pinyin: Ji Zhi). 23 FD can also be divided into various TCM syndromes, which may include, but not limited to: (a) liver-stomach disharmony syndrome; (b) dampness-heat of spleen and stomach syndrome; (3) cold and heat in complexity syndrome; and (4) spleen-stomach weakness syndrome. 24 TCM aims at harmonizing or improving the relationship between different organs and systems in the human body in order to relieve the symptoms of FD. Traditionally, accurate diagnosis of TCM syndrome type is considered a key for guiding the appropriate choice of individualized CHM formula, although the use of CHM without TCM diagnosis is also common.
Existing meta-analyses indicated that, in general, CHM was superior to placebo for improvement of quality of life, alleviation of global dyspeptic symptoms, and reduction of severity from a CHM perspective. 25, 26 When CHM is compared with pharmacotherapy, evidence from existing metaanalyses is inconsistent. Meta-analyses comparing CHM 25,27 or selected specific CHM formula 28 versus pharmacotherapy in general showed that CHM was more effective than pharmacotherapy for the alleviation of global dyspeptic symptoms. Meta-analyses showed CHM in general, 29, 30 or selected specific CHM formulae 31-37 were more effective than prokinetic agents. However, another meta-analysis and one separate trial showed similar effectiveness between CHM and prokinetic agents for the alleviation of global dyspeptic symptoms and global PDS, respectively. 38 For alleviation of FD individual symptoms, meta-analyses showed individual CHM formula was more effective than prokinetic agents, including alleviation of early satiety and epigastric pain, but not for postprandial fullness and epigastric burning. 37 
Objective
The heterogeneous results from existing systematic reviews (SRs) make it difficult to draw conclusions on the effectiveness of CHM over pharmacotherapy. There is a need to perform a SR of SRs to resolve such inconsistency. We conducted a systematic review of SRs to critically appraise and synthesize current clinical evidence on the effectiveness and safety of CHM on FD.
Method

Eligibility criteria
To be included, the SRs should meet the criteria as follows: (a) patients were diagnosed with FD 44 and EMBASE. 45 Detailed search strategies and related results for each database are reported in Table A1 in the appendix. No language restriction was set during the literature search.
Literature selection, data extraction, and methodological quality assessment All the retrieved citations were screened and assessed for eligibility. Data that were extracted from the included SRs were as follows: characteristics of the SR, including first author's name, year of publication, eligibility criteria for selecting primary studies, and number of included studies and patients; details on patient characteristics, details of CHM and control interventions; effect sizes on each outcome of interest, and adverse effects; and risk of bias among RCTs included in the SRs.
The methodological quality of included SRs was appraised by the AMSTAR tool, a reliable and valid tool for methodological quality assessment of SRs. 46, 47 Eleven aspects were assessed using AMSTAR, with each aspect being judged as 'yes', 'no', 'can't answer' or 'not applicable', based on the information provided. The detailed operational guide for AMSTAR is provided in Table  A2 in the appendix.
Literature selection, data extraction, and methodological quality assessment were performed by two researchers (MC and XY) independently. Disagreements were resolved by thorough discussions and consensus adjudication. A third reviewer (VC) would be consulted if disagreement could not be resolved, and his judgment was considered to be the final decision.
Outcomes of interest
Trials results extracted from each meta-analysis should include at least one of the following primary outcomes:
(1) Alleviation of global dyspeptic symptoms, measured by global symptom improvement scale; (2) Alleviation of individual dyspeptic symptoms (epigastric burning, epigastric pain, gastric emptying or fullness), measured by individual symptom improvement scale.
Quality-of-life improvement and safety were considered as the secondary outcomes in this SR.
Data synthesis
The effectiveness of CHM treatments was assessed at SR level according to the Cochrane Handbook. 48 No reanalyzing of the data using network meta-analysis approach was performed due to the insufficient number of trials sharing a common comparator, as well as head-to-head comparison between interventions. We extracted the pooled effect estimation from each meta-analysis. Pooled relative risk (RR) or odds ratio (OR) for dichotomous outcomes, and weighted mean difference (WMD) or standard mean difference (SMD) for continuous outcomes, accompanied by their respective 95% confidence intervals (CIs) were extracted as reported by the meta-analyses.
I-square (I 2 ) values were also extracted for appraising heterogeneity among RCTs. The I 2 value of <25%, 25-50%, >50% were regarded as an indicator for the presence of low, moderate, and high heterogeneity, respectively. 49
Results
Study selection
There were a total of 601 citations retrieved from the database searches. Among them, 12 SRs were found to be eligible and were included in the SR of SRs. Two additional SRs were identified from existing SRs. 26,28 Therefore, 14 SRs were inclu ded. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Details on the study selection process can be found in Figure 1 .
Characteristics of included systematic reviews
The fourteen SRs were published between 2009 and 2016 and all were conducted in China.
Characteristics of these SRs can be found in Table A3 in the appendix.
In the control arm, the included trials applied either conventional pharmacotherapy or placebo of CHM. Six SRs included only trials evaluating domperidone or mosapride in the control group, while seven SRs set no restrictions on conventional pharmacotherapy used in the control group. Among these seven SRs, one of them also included CHM placebo as a control. Therefore, together with another SR accepting CHM placebo as a control, there are two SRs synthesizing evidence on CHM versus CHM placebo comparison.
Methodological quality of included systematic reviews
Overall, the methodological quality of the included SRs was moderate, with 13 SRs (92.9%) having reported the basic characteristics of the included studies. Twelve SRs (85.7%) combined the studies' findings using appropriate methods, assessed the likelihood of publication bias, assessed and documented the scientific quality of the included studies, and their scientific quality was considered appropriately in conclusion formulation. However, only three (21.4%) searched for grey literature and none of them provided a list of included and excluded studies. Details on the methodological quality of included SRs is shown in Table 2 .
Effectiveness of Chinese herbal medicine for functional dyspepsia
Primary outcomes Alleviation of global dyspeptic symptoms. All the included SRs, with a total of 24 comparisons, summarized evidence of CHM on FD (Table 3) . For the intervention arm, there are 13 comparisons focusing on a specific CHM formula. CHM was administered either alone (9 comparisons), or in combination with pharmacotherapy (4 comparisons). There are also 11 comparisons that included multiple types of CHM formulae as intervention, either alone (10 comparisons) or as
Figure1. Flowchart of literature search for systematic reviews on Chinese herbal medicine for functional dyspepsia. Table 2 . Methodological quality of included systematic reviews. an add-on to pharmacotherapy (1 comparison). Table 4 presents a summary of the main findings in this SR.
Author(s)
For the control arm, eight comparisons summarized evidence from specific prokinetic agents, namely mosapride (five comparisons) and domperidone (two comparisons). The remaining one comparison combined the outcome using mosapride or domperidone against CHM to generate a pooled result. On the other hand, 14 comparisons summarized evidence from multiple types of pharmacotherapy, either comparing CHM + pharmacotherapy with pharmacotherapy (4 comparisons) or comparing CHM with pharmacotherapy (10 comparisons). There are also two comparisons between multiple types of CHM and placebo of CHM on global symptom improvement. Details on the results are listed in Table 3 .
Chinese herbal medicine versus pharmacotherapy. In total, there are 17 pooled results on this comparison, either including multiple types of CHM formulae (8 comparisons) or focusing on a single CHM (9 comparisons). Results showed that CHM is generally superior to pharmacotherapy in improving FD global symptoms, as 13 out of 17 comparisons revealed that CHM had higher treatment effectiveness than pharmacotherapy on FD. Among the eight pooled results that included multiple types of CHM formulae, the effect size ranged from a pooled OR of 3.98 (95% CI = 1.50-10.54, I 2 = 0%, two RCTs) to a pooled RR of 1.02 (95% CI = 0.90-1.15, I 2 = 62%, four RCTs).
There were three specific CHM formulae which appeared to show larger effect sizes. * CHM denotes the inclusion of multiple types of Chinese herbal medicine. The generic term 'prokinetic agents' is used to denote that multiple types of prokinetic agents were included in the comparison. The term 'pharmacotherapy' was used when both proton pump inhibitor and prokinetic agents were included in the comparison. If the authors evaluated multiple CHM formulations and provided detailed information, we reported the compositions of herbal formulations in Table A3 in the appendix. ** Alleviation of global or individual dyspeptic symptoms is measured by Gastrointestinal Symptom Rating Scale (GSRS) or other standardized scales. GSRS is a score in which patients report dyspeptic symptom severity on a four-point Likert scale (symptom free, marked improvement, slight improvement, and no improvement). $ p < 0.10 for the heterogeneity test.
‡ 'Obviously effective' rate denotes a numerical result ⩾ 60% in the following calculation: [(Severity score of symptoms before treatment -Severity score of symptoms after treatment) / Severity score of symptoms before treatment] × 100%, with symptoms measured by the GSRS and other standardized scales. Table 3 . # Gastric emptying rate is defined as the GSRS scores in emptying the stomach 25 and as the percentage of substances remaining in stomach 4-5 h after a meal. 37 ‡ ‡ Alleviation of Chinese medicine syndrome measures symptom improvement according to traditional Chinese medical theories and standards. CHM, Chinese herbal medicine; CI, confidence interval; RR, risk ratio; OR, odds ratio; MD, mean difference; SMD, standard mean difference; NA, not applicable. Chinese herbal medicine plus pharmacotherapy versus pharmacotherapy. A total of five SRs reported pooled results of this comparison and four of them restricted the type of CHM formula used. With the combined use of CHM and pharmacotherapy, the add-on effectiveness was obvious, as all of the summarized evidence favored the combined treatment group. Modified Xiao Yao San has a relatively better performance, with pooled OR = 4.71 (95% CI = 2.69-8.25, I 2 = 0%, six RCTs).
Chinese herbal medicine versus placebo. There were two pooled results summarized from 11 RCTs comparing CHM with placebo on the effectiveness on FD. Both showed that CHM was more effective than placebo, with pooled RR being 1.45 (95% CI = 1.31-1.60, I 2 = 8%, seven RCTs) and 1.47 (95% CI = 1.29-1.68, I 2 = 0%, four RCTs), respectively. Both of them did not restrict the types of CHM formula in the analyses.
Alleviation of individual dyspeptic symptoms
Alleviation of fullness sensation. There is one RCT comparing CHM and domperidone on this outcome, showing that CHM performed slightly better in reducing fullness sensation, but the difference did not reach significance (RR: 1.07, 95% CI = 0.93-1.24, 55 patients).
Gastric emptying. There were two meta-analyses on this outcome. One demonstrated that Liu Wei An Xiao capsule had a better gastric emptying effect than prokinetic agents (pooled MD = 2.16, 95% CI = 0.26-4.17, I 2 = 4%, four RCTs). The other one comparing CHM and pharmacotherapy found no significant difference between the two interventions.
Alleviation of epigastric pain. One meta-analysis based on six RCTs revealed that Liu Wei An Xiao capsule was more favorable than pharmacotherapy in reducing epigastric pain, with a pooled RR = 1.18 (95% CI = 1.06-1.31, I 2 = 28%).
Alleviation of epigastric burning. One metaanalysis based on three RCTs showed that there was no significant difference between Liu Wei An Xiao capsule and prokinetic agents, with a pooled RR = 0.98 (95% CI = 0.76-1.26, I 2 = 0%).
Alleviation of postprandial fullness. One metaanalysis summarized from three RCTs revealed that there was no significant difference between Liu Wei An Xiao capsule and pharmacotherapy in alleviation of postprandial fullness, with a pooled RR = 1.06 (95% CI = 0.97-1.16, I 2 = 46%).
Alleviation of early satiety. One meta-analysis from five RCTs demonstrated that Liu Wei An Xiao capsule could relieve early satiety better than prokinetic agents (pooled RR = 1.17, 95% CI = 1.04-1.32, I 2 = 18%).
Secondary outcomes Quality of life.
Three pooled results were reported from two SRs, which did not restrict the use of particular CHM formula. They all showed that CHM improved the quality-of-life scoring of patients to a greater extent as compared with pharmacotherapy or placebo. The most significant pooled MD is 37.87 (95% CI = 20.01-55.73, I 2 = 44%, three RCTs), but moderate heterogeneity is present in this meta-analysis.
Alleviating Chinese medicine syndrome severity. One meta-analysis derived from five RCTs demonstrated that CHM was more effective in reducing severity of Chinese medicine syndrome than placebo, with pooled RR = 1.36 (95% CI = 1.23-1.50, I 2 = 31%).
Safety. Five SRs reported pooled results for safety, with three comparing CHM with pharmacotherapy, one comparing CHM plus pharmacotherapy with pharmacotherapy alone, and the remaining one comparing CHM with placebo. Four pooled results showed that there were no significant differences between the treatment and control groups in causing adverse events. The remaining one reported that CHM was safer than pharmacotherapy, with pooled OR of 0.14 (95% CI = 0.03-0.63, I 2 = 0%, four RCTs) ( Table 3) . Adverse events that could be attributed to CHM treatment include epigastric discomfort, increased passing of flatus, abdominal fullness and more frequent egestion. Details on reported adverse events are shown in Table A3 in the appendix.
Discussion
Evidence from included SRs showed that CHM outperformed pharmacotherapy at improving global and individual dyspeptic symptoms. Three journals.sagepub.com/home/tag 13 specific CHM formulae which appeared to show superior results in the alleviation of global dyspeptic symptoms are Si Ni San, modified Xiao Yao San and Xiang Sha Liu Jun Zi decoction. Taking into consideration the safety of using CHM, available evidence suggested that CHM might be safer than pharmacotherapy. Moreover, even if negative effects occurred, they were mild and tolerated by the patients. Therefore, CHM could be an alternative, or used as an add-on treatment, to pharmacotherapy. Yet, future trials should address methodological shortcomings of existing trials. Many trials contributing to the SR result had unclear risk of bias in terms of sequence generation, allocation concealment and blinding.
To improve the reporting quality, future randomized controlled trials should also comply with the CONSORT reporting guideline. 50 Among the total of 14 SRs, we identified 8 SRs that used specific CHM formulae as intervention, while the remaining six did not restrict their CHM formulae. When there is no restriction on the CHM formulae, the results could only indicate the general effectiveness of CHM. The applicability of such results is limited, as the generalized results from different formulae did not indicate their comparative effectiveness. Therefore, it is difficult to conclude which formula has the highest probability in improving different FD symptoms. Future network meta-analysis and follow-up trials on the most promising CHM formula should be conducted. 51 In routine practice, the prescription of Chinese herbal medicine is often tailored in accordance to the patient's Chinese medicine syndrome type, which is diagnosed via the 'four diagnostic procedure' in Chinese medicine: inspection, auscultation and olfaction, inquiry and palpation. However, only five 30,34,36-38 of the 14 SRs considered Chinese medicine syndrome type as a trial eligibility criterion. In order words, more than 60% of the results reported in this SR only considered the use of CHM for managing FD, without additional consideration of aligning Chinese medicine syndrome type and choice of CHM. This provides a potential explanation on variations in effect sizes reported in different metaanalyses and trials. In improved model validity of future trials, investigators should incorporate Chinese medicine diagnosis into the inclusion criteria. Nevertheless, standardizing Chinese medicine diagnosis for FD has proved difficult, 52 but such obstacles could be resolved by group consensus technique or emerging machine learning methods. 53, 54 During the process of literature selection, we observed a noteworthy problem among the SRs, which is a lack of detailed description of the outcome measurement method. We have therefore excluded 16 SRs from our SR of SRs for this reason. Without a validated outcome measurement approach, the data derived would become hard to interpret. This common flaw should be rectified in future research by providing information on the validity, reliability and responsiveness of the outcome measurement scale or approach. With regards to outcome selection, both objectives, as well as validated patient-centered outcomes should be reported in future trials, including: (a) individual symptom assessment; (b) disease-specific quality of life questionnaire; (c) nutrient drink test; and (d) gastric emptying test. 55 Also, follow-up duration of our included RCTs was only 2-8 weeks. Longer-term benefits of CHM should be evaluated by following the recommended follow-up duration of at least 12 weeks. 55 Also, the external validity of our results is limited by the use of heterogeneous diagnostic criteria for inclusion in different trials. Rome III has been adopted in more than half of the included RCTs, and its application is limited by the fact that it may lead to exclusion of a substantial number of patients with endoscopically verified FD. 56 The application of such a strict inclusion criteria implies that trial patients are likely to differ from the average patient seen in clinical practice. 56 In the newly released Rome IV criteria, only minor modifications were made with regards to symptom description 57 and this problem could persist if future trials continue to adopt Rome IV criteria. In future, more flexible diagnostic criteria might be used in recruiting patients in FD clinical trials. 58 Additionally, since the evidence summarized was obtained from reports published in China, we should take note of the potential publication bias. 59, 60 All participants from our included trials were Chinese, the applicability of our results to other ethnicities is therefore limited.
Among the included SRs, CHM has demonstrated a good safety profile, with adverse drug reactions (ADRs) induced by herbal medicine being generally mild. However, existing evidence has suggested that certain CHM may induce more series adverse events, [61] [62] [63] [64] which highlights the importance of supervision when CHM is prescribed for the treatment of FD.
Finally, it should be highlighted that the methodological quality of SRs regarding CHM is mediocre. Future SR teams should be providing lists of included and excluded studies, and including grey literature in their synthesis. Also, reporting quality of the SRs is less than satisfactory. Only 2 out of the 14 SRs reported the duration of FD diagnosis, which is an importing piece of information for guiding the choice of appropriate treatment for patients with different duration of diagnosis. Six of them did not report details of treatment regimens, including the frequency and dosage. This hinders the translation of research findings into daily practice. It is also noteworthy that some meta-analysis pooled trial data used OR instead of RR. This is not a preferred practice, as RR should be use for quantifying RCT results. The use of OR would lead to exaggeration of effect sizes and readers should be cautious when interpreting these results. 65 In conclusion, current clinical evidence has revealed that CHM can be considered an option for FD treatment. Future trials can focus on the improvement of individual dyspeptic symptoms, including PDS and EPS, together with global symptom improvement, in order to provide a more comprehensive and detailed analysis. In addition, the methodological and reporting qualities of future SRs and clinical trials have to be improved urgently, with adherence to international standards.
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